summary: heart diagnosis announced the results of a budget impact modeling study on an AI-powered multi-ohm DNA test designed to detect stable coronary heart disease. $113.6 million annually for a health insurance plan with 1 million members.

Key points:

1. Using the PrecisionCHD test for initial assessment of coronary heart disease can result in significant cost savings for healthcare providers and insurance companies. $113.6 million per year for a health plan serving 1 million members.
2. PrecisionCHD utilizes a combination of six DNA methylation and ten genetic biomarkers analyzed through a proprietary machine learning model. The sensitivity was 79% and the specificity was 76%, demonstrating its effectiveness in accurately detecting stable CHD.
3. The test uses Current Procedural Terminology (CPT) codes. american medical association Innovation technology agreement with Visitant.

Cardio Diagnostics Holdingsa provider of next-generation precision cardiovascular medical technology that leverages AI algorithms with epigenetic and genetic biomarkers, is investing in PrecisionCHD, its AI-powered multi-ohm coronary heart disease detection test. Announcing the publication of the results of an impact modeling study.

A peer-reviewed study published in the journal Advances in Therapy, “Using precision epigenetic techniques to diagnose and care for stable coronary heart disease reduces healthcare costs,” found that the use of PrecisionCHD It has been reported that the cost of secondary prevention of coronary heart disease can be significantly reduced.Due to disease (CHD) $113.6 million According to the company, a typical health insurance plan with 1 million members would have an annual premium of 1 million yen.

DNA testing for coronary heart disease using AI

PrecisionCHD is an AI-powered multi-ohm DNA test that uses epigenetic and genetic biomarkers to help detect stable coronary heart disease. This blood-based test assesses 6 DNA methylation and 10 genetic biomarkers and uses a proprietary machine learning model to interpret genetically contextual methylation signals from these biomarkers. Masu. The sensitivity and specificity of this test are Mountain healthcare and University of Iowa Hospitals and Clinics recently, American Heart Association Journal.

Reducing the cost of coronary heart disease testing

The PrecisionCHD Budget Impact Model is designed to replace currently commonly used tests such as exercise electrocardiograms, coronary computed tomography angiography (CCTA), and angiography as the primary method for initial assessment of coronary heart disease. Designed to evaluate cost savings associated with using PrecisionCHD. The model took into account factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions. This result suggests that using PrecisionCHD can lead to significant cost savings for payers. $113.6 million Annual savings for a 1 million member plan. These savings are primarily driven by the lower cost of PrecisionCHD compared to traditional testing and reduced need for additional testing. The model also found that cost savings were independent of patient demographics or insurance plan design. Similar results were observed for plans that exclude Medicare enrollees, include only Medicare enrollees (Part B or Medicare Advantage), and offer high coinsurance rates. The company says it will offer even higher co-pays.

“The data from this study suggest that widespread use of PrecisionCHD as an initial test to detect coronary heart disease has the potential to generate significant savings for payers.” Masu. david frisvoldPh.D., Associate Professor Faculty of Economics in University of Iowa He is also the study’s lead author. “More importantly, the reported cost savings have been shown to be generalizable to a variety of health plans, potentially leading to increased access to care and improved outcomes for CHD patients. is.”

PrecisionCHD was recently awarded Current Procedural Terminology (CPT) Proprietary Clinical Laboratory Examination (PLA) code 0449U by the U.S. government agency. american medical association it is now enabled April 1, 2024. PrecisionCHD has also been awarded innovation technology contracts from the following companies: Visitantthe nation’s largest group purchasing organization, with a customer base covering more than 60% of U.S. hospitals and more than 97% of academic medical centers. US.